Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccines

Cancer Gene Therapy volume 18, pages 563–570 (2011)Cite this article

Subjects

Abstract

Dendritic cell (DC) vaccines have shown great promise in generating antitumor immune responses but have generally fallen short of producing durable cures. Determining mechanisms by which these vaccines fail will provide one strategy toward improving their success. Several manipulations of DCs have improved their migration and longevity, but the immune inhibitory environment surrounding tumors provides a powerful suppressive influence. To determine the mechanisms by which DCs at the site of the tumor convert to a suppressive phenotype, we evaluated pathways in DCs that become expressed at the tumor site. Our results revealed that tumors lead to induction of the glucocorticoid-induced leucine zipper (GILZ) gene in DCs, and that this gene is critical for the development of tumor-induced tolerance of both DCs and T cells. Previous data suggested that GILZ is a pivotal gene in the balance between activation and tolerance of DCs. Our new data show that GILZ is highly upregulated in DCs in the tumor microenvironment in vivo and that blockade of this gene in DC vaccines significantly improves long-term survival. These results suggest that GILZ may be an ideal candidate gene to target for novel immune-based tumor therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68: 5955–5964.

    Article  CAS  Google Scholar 

  2. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842–847.

    CAS  PubMed  Google Scholar 

  3. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11: 4160–4167.

    Article  CAS  Google Scholar 

  4. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C . Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 2008; 15: 114–121.

    Article  CAS  Google Scholar 

  5. Mule JJ . Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann N Y Acad Sci 2009; 1174: 33–40.

    Article  CAS  Google Scholar 

  6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–332.

    Article  CAS  Google Scholar 

  7. Pecher G, Haring A, Kaiser L, Thiel E . Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002; 51: 669–673.

    Article  CAS  Google Scholar 

  8. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15: 4986–4992.

    Article  CAS  Google Scholar 

  9. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 2008; 20: 1305–1311.

    PubMed  Google Scholar 

  10. Lehrfeld TJ, Lee DI . Dendritic cell vaccines for the treatment of prostate cancer. Urol Oncol 2008; 26: 576–580.

    Article  CAS  Google Scholar 

  11. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009; 49: 124–132.

    Article  Google Scholar 

  12. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008; 22: 1007–1017.

    Article  CAS  Google Scholar 

  13. Palma M, Adamson L, Hansson L, Kokhaei P, Rezvany R, Mellstedt H et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother 2008; 57: 1705–1710.

    Article  CAS  Google Scholar 

  14. Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008; 40: 108–116.

    Article  CAS  Google Scholar 

  15. Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother 2004; 53: 777–785.

    Article  Google Scholar 

  16. Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009; 11: 653–668.

    Article  CAS  Google Scholar 

  17. Melief CJ . Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372–383.

    Article  CAS  Google Scholar 

  18. Kim SO, Ono K, Tobias PS, Han J . Orphan nuclear receptor Nur77 is involved in caspase-independent macrophage cell death. J Exp Med 2003; 197: 1441–1452.

    Article  CAS  Google Scholar 

  19. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171: 2970–2976.

    Article  CAS  Google Scholar 

  20. Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005; 65: 309–316.

    CAS  PubMed  Google Scholar 

  21. Wang T, Jiang Q, Chan C, Gorski KS, McCadden E, Kardian D et al. Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR. Blood 2009; 113: 2906–2913.

    Article  CAS  Google Scholar 

  22. Shortman K, Lahoud MH, Caminschi I . Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med 2009; 41: 61–66.

    Article  CAS  Google Scholar 

  23. Terando A, Roessler B, Mule JJ . Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004; 11: 165–173.

    Article  CAS  Google Scholar 

  24. D’Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803–812.

    Article  Google Scholar 

  25. Ayroldi E, Riccardi C . Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. Faseb J 2009; 23: 3649–3658.

    Article  CAS  Google Scholar 

  26. Shibanuma M, Kuroki T, Nose K . Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor beta 1 and other growth factors. J Biol Chem 1992; 267: 10219–10224.

    CAS  PubMed  Google Scholar 

  27. Schoenenberger GA, Cueni LB, Monnier M, Hatt AM . Humoral transmission of sleep. VII. Isolation and physical-chemical characterization of the ‘sleep inducing factor delta’. Pflugers Arch 1972; 338: 1–17.

    Article  CAS  Google Scholar 

  28. Asselin-Labat ML, Biola-Vidamment A, Kerbrat S, Lombes M, Bertoglio J, Pallardy M . FoxO3 mediates antagonistic effects of glucocorticoids and interleukin-2 on glucocorticoid-induced leucine zipper expression. Mol Endocrinol 2005; 19: 1752–1764.

    Article  CAS  Google Scholar 

  29. Cannarile L, Cuzzocrea S, Santucci L, Agostini M, Mazzon E, Esposito E et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology 2009; 136: 530–541.

    Article  CAS  Google Scholar 

  30. Cohen N, Mouly E, Hamdi H, Maillot MC, Pallardy M, Godot V et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 2006; 107: 2037–2044.

    Article  CAS  Google Scholar 

  31. Hamdi H, Bigorgne A, Naveau S, Balian A, Bouchet-Delbos L, Cassard-Doulcier AM et al. Glucocorticoid-induced leucine zipper: a key protein in the sensitization of monocytes to lipopolysaccharide in alcoholic hepatitis. Hepatology 2007; 46: 1986–1992.

    Article  Google Scholar 

  32. Berrebi D, Bruscoli S, Cohen N, Foussat A, Migliorati G, Bouchet-Delbos L et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003; 101: 729–738.

    Article  CAS  Google Scholar 

  33. Godot V, Garcia G, Capel F, Arock M, Durand-Gasselin I, Asselin-Labat ML et al. Dexamethasone and IL-10 stimulate glucocorticoid-induced leucine zipper synthesis by human mast cells. Allergy 2006; 61: 886–890.

    Article  CAS  Google Scholar 

  34. Whartenby KA, Straley EE, Kim H, Racke F, Tanavde V, Gorski KS et al. Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002; 100: 3147–3154.

    Article  CAS  Google Scholar 

  35. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF . Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009; 20: 1106–1118.

    Article  CAS  Google Scholar 

  36. Zhang W, Chen Z, Li F, Kamencic H, Juurlink B, Gordon JR et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003; 108: 177–188.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was funded by R01CA111989.

Author information

Authors and Affiliations

  1. Department of Neurology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    L Lebson & K A Whartenby

  2. LCMB/NCI, National Institutes of Health, Bethesda, MD, USA

    T Wang

  3. Qiagen, Frederick, MD, USA

    Q Jiang

  4. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    K A Whartenby

Authors
  1. L Lebson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Q Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K A Whartenby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K A Whartenby.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lebson, L., Wang, T., Jiang, Q. et al. Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccines. Cancer Gene Ther 18, 563–570 (2011). https://doi.org/10.1038/cgt.2011.23

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2011.23

Keywords

This article is cited by

Search

Advanced search

Quick links